ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cyramza (ramucirumab) by Year
Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Cyramza (ramucirumab): 0.0% in FY2023, up 6.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2023
0.0%
Period ended Dec 31, 2023
Change on a year earlier
+6.0 pts
-6.0% in FY2022
History
7 years
Since FY2017
Sources
7
Documents cited below
Where the FY2023 figure comes from
“|| Cyramza ® | 253.6 | 277.8 | (9)% | 974.7 | 971.4 | 0%”
Source: Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0.0% | +6.0 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | -6.0% | -6.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 0.0% | -12.0 pts | Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 12.0% | +4.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 8.0% | -15.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 23.0% | -37.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 60.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cyramza (ramucirumab) (%), annual FY2017–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cyramza-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.